home / stock / harp / harp articles

HARP Articles, Harpoon Therapeutics Inc. - From 11/02/23

Stock Information
Company Name: Harpoon Therapeutics Inc.
Stock Symbol: HARP
Market: NYSE
Website: harpoontx.com
Menu
HARP HARP Quote HARP Short HARP News HARP Articles HARP Message Board
Get HARP Alerts

News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition | Benzinga

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company...
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket | Benzinga

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares jumped 232% to $3.36 in pre-market trading. United Therapeutics Corporation (N...

Why Logitech International Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket | Benzinga

Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares surged 91.2% to $0.2180 in pre-market trading after falling 10% on Monday. Ascent Solar Tec...

Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. L...
What's Going On With Harpoon Therapeutics Stock Monday? | Benzinga

Harpoon Therapeutics Inc (NASDAQ: HARP) shares are trading higher Monday after the company announced updated data from a trial evaluating ...

Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket | Benzinga

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration...

Harpoon Therapeutics Announces Up to $150 Million Private Placement | Benzinga

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP) (the "Company"), a clinical-stage immun...
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023 | Benzinga

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company...

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 | Benzinga

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company...

Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting | Benzinga

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No I...
Previous 10 Next 10